Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 11-19 of 19

Page
per page
  1. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  2. Bafetinib (INNO-406)
    B1011 Bafetinib (INNO-406)
     2 Citation
    Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor
      ≥57.7 mg/mL
  3. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL
  4. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
  5. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  6. GNF 5
    A8604 GNF 5
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor
  7. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  8. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  9. PD 166326
    C3677 PD 166326
    Summary: receptor tyrosine kinases inhibitor
      ≤25 mg/mL

Items 11-19 of 19

Page
per page